Crossmark

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-017-4145-4

Published Online: 2017-02-11

Published Print: 2017-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Thomas, J. S. https://orcid.org/0000-0002-4652-610X
Hanby, A. M.

Russell, N.

van Tienhoven, G.

Riddle, K.

Anderson, N.

Cameron, D. A.

Bartlett, J. M. S.

Piper, T.

Cunningham, C.

Canney, P.

Kunkler, I. H.
Funding

Funding for this research was provided by:

Medical Research Council (EME 09/800/31)
License Information

License valid from 2017-02-11

Document is current

Any future updates will be listed below